GHRP-6

What it is

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide developed in the 1980s as one of the original GHRPs. It acts as a ghrelin receptor agonist stimulating GH release. The development of GHRP-6 was important historically — it was among the first compounds shown to activate what would later be identified as the ghrelin receptor.

GHRP-6 is most commonly recognized for its appetite-stimulating effects, which are substantially greater than those of other GHRPs. This appetite stimulation can be useful in some specific clinical contexts (e.g., cancer cachexia or severe wasting) but is generally undesirable in modern GH-axis protocols where weight management is often a goal.

Mechanism of action

GHRP-6 binds the ghrelin receptor (GHS-R1a) with effects on:

• GH release: potent, similar to other GHRPs
• Appetite stimulation: substantial — often described as the most appetite-stimulating of the GHRPs. This reflects the natural appetite-stimulating role of ghrelin signaling.
• Cortisol elevation: modest increases similar to GHRP-2
• Prolactin elevation: mild
• GI motility effects: consistent with ghrelin’s role in gastric function

Clinical use

GHRP-6 has been studied for various GH-axis applications and for cachexia and wasting syndromes where appetite stimulation is therapeutically desired. It has not received FDA approval for any indication. Available through licensed compounding pharmacies for clinical use.

Why we don’t prescribe it at The Tide

The appetite stimulation that defines GHRP-6 makes it problematic for our typical patient population:

• Most patients seeking GH-axis support are also working on body composition and metabolic goals where appetite stimulation is counterproductive
• The cortisol and prolactin effects (similar to GHRP-2) add additional concerns
• Modern selective GHRPs (ipamorelin) provide GH release without these off-target effects

For the rare clinical scenario where appetite stimulation is therapeutically desired (e.g., severe wasting), GHRP-6 might be considered, but these scenarios fall outside our typical practice scope and would be appropriately managed by oncology or specialty care.

Side effects and contraindications

Significant appetite stimulation, cortisol elevation, prolactin effects, GI symptoms, and standard GH-axis side effects (joint discomfort, water retention, paresthesias). Contraindicated in malignancy, pregnancy, pituitary disease, severe obesity, uncontrolled diabetes.